复发/难治性神经母细胞瘤中的 TIL 治疗:从免疫生物学到早期临床试验的转化路线图
TIL therapy in relapsed/refractory neuroblastoma: A translational roadmap from immunobiology to early-phase trials.
复发或难治性神经母细胞瘤(R/R NB)是最具挑战性的儿科癌症之一,长期生存率低于 20%。
ALL SOURCES
TIL therapy in relapsed/refractory neuroblastoma: A translational roadmap from immunobiology to early-phase trials.
复发或难治性神经母细胞瘤(R/R NB)是最具挑战性的儿科癌症之一,长期生存率低于 20%。
B7-H3 in Cancer Immunotherapy-Prospects and Challenges: A Review of the Literature.
在当今的肿瘤学中,免疫治疗成为常规癌症治疗的有力补充,使患者能够获得更好的结局。
Correction: Lutskovich et al. Comparative Preclinical Analysis of Anti-B7-H3 CAR-T Cells Targeting Neuroblastoma. Biomedicines 2025, 13, 2130.
在原始出版物中[...]。
Ex vivo-expanded and activated haploidentical natural killer cells infusion before autologous stem cell transplantation in high-risk neuroblastoma: a
我们的研究表明,在高危神经母细胞瘤(NB)患儿中,将 NK 细胞输注纳入 AHSCT 前预处理方案作为巩固治疗的一部分,是安全且耐受性良好的。
Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective Treatment.
背景/目的:高危神经母细胞瘤(HR-NB)是儿童癌症相关死亡的主要原因之一。
Immunotherapy for neuroblastoma by hematopoietic cell transplantation and post-transplant immunomodulation.
神经母细胞瘤是一种相对常见的儿童肿瘤,给治疗带来了困难。
Organoid-Immune Co-Cultures: A Next-Generation approach to disease modeling.
将类器官与免疫细胞结合在共培养系统中,标志着癌症研究和免疫学领域的突破性进展。
The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis.
靶向 GD2 抗原的 CAR-T 细胞疗法在治疗 NB 方面前景广阔。
Synergistic antitumor effects of recombinant Interleukin-21 and 5-fluorouracil: A novel therapeutic approach against hepatocellular carcinoma.
MTT 活力检测结果显示,单用 rhIL-21 处理 HepG2 细胞后,24 h 和 48 h 的细胞毒性分别为 54.81 % 和 59.75 %,相应的 IC50 值分别为 108 ng/mL 和 68.90 ng/mL。
Comparative Preclinical Analysis of Anti-B7-H3 CAR-T Cells Targeting Neuroblastoma.
背景:神经母细胞瘤是一种儿童肿瘤,高危患者一旦复发通常致命。
MEMBER ACCOUNT
登录成功会直接打开下一页。